• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

真相的半衰期:研究决策的合适时间范围是什么?

The half-life of truth: what are appropriate time horizons for research decisions?

作者信息

Philips Zoe, Claxton Karl, Palmer Stephen

机构信息

Centre for Health Economics, University of York, York, YO10 5DD [corrected] UK.

出版信息

Med Decis Making. 2008 May-Jun;28(3):287-99. doi: 10.1177/0272989X07312724. Epub 2008 Apr 30.

DOI:10.1177/0272989X07312724
PMID:18448701
Abstract

PURPOSE

To evaluate alternative approaches taken to estimate the population that could benefit from research and to demonstrate that explicitly modeling future change leads to more appropriate estimates of the expected value of information (EVI).

METHODS

Existing approaches to estimating the population typically focus on the time horizon for decisions, employing seemingly arbitrary estimates of the appropriate horizon. These approaches implicitly use the time horizon as a proxy for future changes in technologies, prices, and information. Different approaches to quantifying the time horizon are explored, in the context of a stylized model, to demonstrate the impact of uncertainty in this estimate on EVI. An alternative approach is developed that explicitly models future changes in technologies, prices, and information and that demonstrates the impact on EVI estimates.

RESULTS

Explicitly modeling future changes means that the EVI for the decision problem may increase or decrease over time, but the EVI for the group of parameters that can be evaluated by current research tends to decline. The finite and infinite time horizons for the decision problem represent special cases (e.g., price shock or no changes, respectively). This type of analysis can be used to inform policy decisions relating to the timing of research.

CONCLUSIONS

The value of information depends on future changes in technologies, prices, and evidence. Finite time horizons for decision problems can be seen as a proxy for the complex and uncertain process of future change. A more explicit approach to modeling these changes could provide a more appropriate basis for calculating EVI, but this raises a number of significant methodological and technical challenges.

摘要

目的

评估用于估计可能从研究中受益的人群的替代方法,并证明明确模拟未来变化会得出对信息期望值(EVI)更合适的估计。

方法

现有的估计人群的方法通常侧重于决策的时间范围,采用对合适时间范围看似随意的估计。这些方法隐含地将时间范围用作技术、价格和信息未来变化的代理。在一个简化模型的背景下,探索了量化时间范围的不同方法,以证明该估计中的不确定性对EVI的影响。开发了一种替代方法,该方法明确模拟技术、价格和信息的未来变化,并展示其对EVI估计的影响。

结果

明确模拟未来变化意味着决策问题的EVI可能随时间增加或减少,但当前研究可评估的参数组的EVI往往会下降。决策问题的有限和无限时间范围代表特殊情况(例如,分别为价格冲击或无变化)。这种类型的分析可用于为与研究时机相关的政策决策提供信息。

结论

信息的价值取决于技术、价格和证据的未来变化。决策问题的有限时间范围可被视为未来变化这一复杂且不确定过程的代理。对这些变化进行建模的更明确方法可为计算EVI提供更合适的基础,但这带来了一些重大的方法和技术挑战。

相似文献

1
The half-life of truth: what are appropriate time horizons for research decisions?真相的半衰期:研究决策的合适时间范围是什么?
Med Decis Making. 2008 May-Jun;28(3):287-99. doi: 10.1177/0272989X07312724. Epub 2008 Apr 30.
2
Generalisability in economic evaluation studies in healthcare: a review and case studies.医疗保健经济评估研究中的可推广性:综述与案例研究
Health Technol Assess. 2004 Dec;8(49):iii-iv, 1-192. doi: 10.3310/hta8490.
3
Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.基于组织学的癌症药物建模方法,为 NICE 评估提供信息:系统评价和决策框架。
Health Technol Assess. 2021 Dec;25(76):1-228. doi: 10.3310/hta25760.
4
An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis.一项关于静脉注射免疫球蛋白治疗脓毒症(严重脓毒症和感染性休克)的多中心随机对照试验的可行性、成本和信息价值评估:包括系统评价、荟萃分析和信息价值分析。
Health Technol Assess. 2012;16(7):1-186. doi: 10.3310/hta16070.
5
Causal evidence in health decision making: methodological approaches of causal inference and health decision science.健康决策中的因果证据:因果推断方法和健康决策科学。
Ger Med Sci. 2022 Dec 21;20:Doc12. doi: 10.3205/000314. eCollection 2022.
6
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
7
Lifetime earnings patterns, the distribution of future Social Security benefits, and the impact of pension reform.终身收入模式、未来社会保障福利的分配以及养老金改革的影响。
Soc Secur Bull. 2000;63(4):74-98.
8
Estimating Value-Based Price and Quantifying Uncertainty around It in Health Technology Assessment: Frequentist and Bayesian Approaches.健康技术评估中基于价值的价格估算及其不确定性的量化:频率派和贝叶斯方法。
Med Decis Making. 2022 Jul;42(5):672-683. doi: 10.1177/0272989X221079554. Epub 2022 Feb 16.
9
Are value of information methods ready for prime time? An application to alternative treatment strategies for NSTEMI patients.信息价值方法是否已准备好进入黄金时代?一项针对非ST段抬高型心肌梗死患者替代治疗策略的应用。
Int J Technol Assess Health Care. 2013 Oct;29(4):435-42. doi: 10.1017/S0266462313000433.
10

引用本文的文献

1
Invasive urodynamic investigations in the management of women with refractory overactive bladder symptoms: FUTURE, a superiority RCT and economic evaluation.侵入性尿动力学检查在难治性膀胱过度活动症女性患者管理中的应用:FUTURE,一项优效性随机对照试验及经济学评估
Health Technol Assess. 2025 Jul;29(27):1-139. doi: 10.3310/UKYW4923.
2
Calculating the Expected Net Benefit of Sampling for Survival Data: A Tutorial and Case Study.计算生存数据抽样的预期净收益:教程与案例研究。
Med Decis Making. 2024 Oct;44(7):719-741. doi: 10.1177/0272989X241279459. Epub 2024 Sep 20.
3
Rapid Assessment of the Need for Evidence: Applying the Principles of Value of Information to Research Prioritisation.
快速评估证据需求:将信息价值原则应用于研究优先级排序。
Pharmacoeconomics. 2024 Sep;42(9):919-928. doi: 10.1007/s40273-024-01403-w. Epub 2024 Jun 20.
4
Cost-utility and value of information analysis of tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma in the Irish healthcare setting.在爱尔兰医疗环境中,替沙格赛基因治疗复发/难治性弥漫性大B细胞淋巴瘤的成本效用和信息价值分析。
J Mark Access Health Policy. 2023 Jan 18;11(1):2166375. doi: 10.1080/20016689.2023.2166375. eCollection 2023.
5
The economics of adaptations to evidence-based practices.基于证据的实践的适应经济学。
Implement Sci Commun. 2022 Sep 24;3(1):100. doi: 10.1186/s43058-022-00345-8.
6
Value of Information Analysis in Models to Inform Health Policy.用于为卫生政策提供信息的模型中的信息价值分析
Annu Rev Stat Appl. 2022 Mar 7;9:95-118. doi: 10.1146/annurev-statistics-040120-010730.
7
Calculating Expected Value of Sample Information Adjusting for Imperfect Implementation.计算样本信息的期望值,同时调整不完善实施的影响。
Med Decis Making. 2022 Jul;42(5):626-636. doi: 10.1177/0272989X211073098. Epub 2022 Jan 16.
8
Cost-Utility Analysis of Prophylactic Dextrose Gel vs Standard Care for Neonatal Hypoglycemia in At-Risk Infants.预防性葡萄糖凝胶与标准护理在高危婴儿新生儿低血糖中的成本-效用分析。
J Pediatr. 2020 Nov;226:80-86.e1. doi: 10.1016/j.jpeds.2020.06.073. Epub 2020 Jul 4.
9
Value of Information Analytical Methods: Report 2 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force.价值信息分析方法:ISPOR 价值信息分析新兴良好实践工作组报告 2 号。
Value Health. 2020 Mar;23(3):277-286. doi: 10.1016/j.jval.2020.01.004.
10
Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-World Experiment.建模选择对信息价值分析的影响:来自真实实验的实证分析。
Pharmacoeconomics. 2020 Feb;38(2):171-179. doi: 10.1007/s40273-019-00848-8.